Moving faster than planned, AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

https://cdn.geekwire.com/wp-content/uploads/2025/11/AccipiterBio_3DHero_DualAgonist_Transp_v2041-1260x1153.png" width="1260" />
Seattle biotech startup Accipiter Bio has raised an additional $10.5 million from existing investors to accelerate its work on AI-designed, multi-target protein therapeutics.

Fueled by faster-than-expected progress, the company plans to use the new capital to expand its team and double its roster of clinical-stage drug candidates, with a growing focus on immunology. https://www.geekwire.com/2026/moving-faster-than-planned-ai-drug-developer-accipiter-bio-quietly-tops-up-seed-round-with-10-5m/">Read More